LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes
Open Access
- 21 October 2017
- journal article
- review article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 89 (5), 526-534
- https://doi.org/10.1136/jnnp-2017-315720
Abstract
Recent biochemical observations have helped redefine antigenic components within the voltage-gated potassium channel (VGKC) complex. The related autoantibodies may be now divided into likely pathogenic entities, which target the extracellular domains of leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (CASPR2), and species that target intracellular neuronal components and are likely non-pathogenic. This distinction has enhanced clinical practice as direct determination of LGI1 and CASPR2 antibodies offers optimal sensitivity and specificity. In this review, we describe and compare the clinical features associated with pathogenic LGI1 and CASPR2 antibodies, illustrate emerging laboratory techniques for antibody determination and describe the immunological mechanisms that may mediate antibody-induced pathology. We highlight marked clinical overlaps between patients with either LGI1 or CASPR2 antibodies that include frequent focal seizures, prominent amnesia, dysautonomia, neuromyotonia and neuropathic pain. Although occurring at differing rates, these commonalities are striking and only faciobrachial dystonic seizures reliably differentiate these two conditions. Furthermore, the coexistence of both LGI1 and CASPR2 antibodies in an individual occurs surprisingly frequently. Patients with either antibody respond well to immunotherapies, although systematic studies are required to determine the magnitude of the effect beyond placebo. Finally, data have suggested that CASPR2 and LGI1 modulation via genetic or autoimmune mechanisms may share common intermediate molecules. Taken together, the biochemical distinction of antigenic targets has led to important clinical advances for patient care. However, the striking syndrome similarities, coexistence of two otherwise rare antibodies and molecular insights suggest the VGKC complex may yet be a common functional effector of antibody action. Hence, we argue for a molecular evolution alongside a clinical and phenotypic re-evaluation.Keywords
Funding Information
- Epilepsy Research UK
- British Medical Association
- Wellcome Trust
This publication has 53 references indexed in Scilit:
- LGI1 tunes intrinsic excitability by regulating the density of axonal Kv1 channelsProceedings of the National Academy of Sciences of the United States of America, 2017
- CASPR2 autoantibodies are raised during pregnancy in mothers of children with mental retardation and disorders of psychological development but not autismJournal of Neurology, Neurosurgery & Psychiatry, 2017
- Anti‐LGI1 encephalitis is associated with unique HLA subtypesAnnals of Neurology, 2016
- Anti‐contactin‐associated protein‐2 encephalitis: relevance of antibody titres, presentation and outcomeEuropean Journal of Neurology, 2016
- Anti-LGI1–associated cognitive impairmentNeurology, 2016
- Antibodies to GABA A receptor α1 and γ2 subunitsNeurology, 2015
- Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotypeBrain, 2013
- Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxiaJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsyNeurology, 2007
- Recessive Symptomatic Focal Epilepsy and Mutant Contactin-Associated Protein-like 2New England Journal of Medicine, 2006